Dynavax Europe

Dynavax is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative vaccines to provide protection against infectious diseases. The company's flagship product, HEPLISAV-B, is the first and only adult hepatitis B vaccine approved in the U.S. and Europe that utilizes a two-dose regimen completed in one month. Dynavax leverages its proprietary CpG 1018 adjuvant, a Toll-like receptor 9 (TLR9) agonist, to enhance the immune response across its pipeline and through various global partnerships. The company is actively advancing clinical programs for shingles and Tdap vaccines while maintaining a robust commercial infrastructure for its hepatitis B franchise.